Revolution Medicines is a biotechnology company focused on developing targeted therapies for cancer and other serious diseases. Its core products include small molecule inhibitors designed to address specific genetic mutations in tumors. The company operates primarily in the healthcare sector, with major revenue sources stemming from partnerships, collaborations, and potential future product sales.
The investment profile of Revolution Medicines may appeal more to growth investors due to its focus on innovative therapies and potential for future revenue generation. However, the high risk associated with its current financial performance and lack of profitability suggests caution. The stock may not be suitable for dividend or value investors at this time.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-06-03 02:51 | Hold | Sell | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-22 02:58 | Sell | Hold | High growth but significant losses and uncertainty remain. |
| 2026-05-08 14:57 | — | Sell | Weak fundamentals and negative momentum raise significant risk. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-06-09 13:24 | UBS | Update | — → 175 | 148.4461 |
| 2026-06-02 09:03 | RBC Capital | Target Raised | — → 182 | 163.68 |
| 2026-06-01 14:33 | H.C. Wainwright | Target Raised | 169 → 195 | 162.51 |
